CU20180027A7 - DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN - Google Patents
DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENENInfo
- Publication number
- CU20180027A7 CU20180027A7 CUP2018000027A CU20180027A CU20180027A7 CU 20180027 A7 CU20180027 A7 CU 20180027A7 CU P2018000027 A CUP2018000027 A CU P2018000027A CU 20180027 A CU20180027 A CU 20180027A CU 20180027 A7 CU20180027 A7 CU 20180027A7
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutical compositions
- 11clk1
- dyrk
- pyrimidine
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1559259A FR3041640B1 (fr) | 2015-09-30 | 2015-09-30 | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| PCT/EP2016/073403 WO2017055533A1 (en) | 2015-09-30 | 2016-09-30 | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20180027A7 true CU20180027A7 (es) | 2018-07-05 |
Family
ID=54979756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2018000027A CU20180027A7 (es) | 2015-09-30 | 2016-09-30 | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20180273538A1 (enExample) |
| EP (1) | EP3356364A1 (enExample) |
| JP (1) | JP2018533552A (enExample) |
| KR (1) | KR20180054856A (enExample) |
| CN (1) | CN108137582A (enExample) |
| AU (1) | AU2016333508A1 (enExample) |
| BR (1) | BR112018005851A2 (enExample) |
| CA (1) | CA2999937A1 (enExample) |
| CL (1) | CL2018000786A1 (enExample) |
| CO (1) | CO2018003466A2 (enExample) |
| CR (1) | CR20180176A (enExample) |
| CU (1) | CU20180027A7 (enExample) |
| DO (1) | DOP2018000082A (enExample) |
| EA (1) | EA201890820A1 (enExample) |
| EC (1) | ECSP18023286A (enExample) |
| FR (1) | FR3041640B1 (enExample) |
| HK (1) | HK1255467A1 (enExample) |
| IL (1) | IL258231A (enExample) |
| MA (1) | MA43021A (enExample) |
| MX (1) | MX2018003861A (enExample) |
| NI (1) | NI201800042A (enExample) |
| PE (1) | PE20190337A1 (enExample) |
| PH (1) | PH12018500605A1 (enExample) |
| SV (1) | SV2018005656A (enExample) |
| TN (1) | TN2018000087A1 (enExample) |
| WO (1) | WO2017055533A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102054910B1 (ko) * | 2017-12-19 | 2019-12-12 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| EP3856186A4 (en) * | 2018-09-28 | 2022-07-06 | Arizona Board of Regents on behalf of the University of Arizona | SMALL MOLECULAR DYRK1/CLK INHIBITORS AND USES THEREOF |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| AR120799A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| CN116783198B (zh) * | 2020-12-02 | 2025-10-21 | 广东弘烨医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| WO2022245776A1 (en) * | 2021-05-20 | 2022-11-24 | Saint John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
| WO2023064349A1 (en) * | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| TW202330533A (zh) * | 2021-10-12 | 2023-08-01 | 美商生物銜接醫療公司 | 7h-吡咯并[2,3-d]嘧啶及其製備及用途 |
| MX2024004552A (es) | 2021-10-12 | 2024-06-04 | Biosplice Therapeutics Inc | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas. |
| WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| CN116621843B (zh) * | 2022-06-13 | 2024-05-24 | 四川大学华西医院 | 一种dna甲基转移酶1抑制剂及其制备方法和用途 |
| CN115785134B (zh) * | 2022-10-28 | 2023-08-29 | 浙大城市学院 | 一种含氮杂环的硼酸化合物及制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008041053A2 (en) | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| JP2009511527A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体 |
| CA2645343A1 (en) | 2006-03-11 | 2007-09-20 | Vernalis (R&D) Limited | Pyrrolopyrimidine derivatives used as hsp90 inhibitors |
| FR2912744B1 (fr) * | 2007-02-16 | 2012-09-07 | Centre Nat Rech Scient | Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| EA025186B1 (ru) * | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| EP3083618B1 (en) * | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
-
2015
- 2015-09-30 FR FR1559259A patent/FR3041640B1/fr not_active Expired - Fee Related
-
2016
- 2016-09-30 AU AU2016333508A patent/AU2016333508A1/en not_active Abandoned
- 2016-09-30 CR CR20180176A patent/CR20180176A/es unknown
- 2016-09-30 PE PE2018000410A patent/PE20190337A1/es unknown
- 2016-09-30 EP EP16774684.1A patent/EP3356364A1/en not_active Withdrawn
- 2016-09-30 TN TNP/2018/000087A patent/TN2018000087A1/en unknown
- 2016-09-30 BR BR112018005851A patent/BR112018005851A2/pt not_active Application Discontinuation
- 2016-09-30 MA MA043021A patent/MA43021A/fr unknown
- 2016-09-30 CN CN201680058179.3A patent/CN108137582A/zh not_active Withdrawn
- 2016-09-30 KR KR1020187012166A patent/KR20180054856A/ko not_active Withdrawn
- 2016-09-30 US US15/763,626 patent/US20180273538A1/en not_active Abandoned
- 2016-09-30 EA EA201890820A patent/EA201890820A1/ru unknown
- 2016-09-30 WO PCT/EP2016/073403 patent/WO2017055533A1/en not_active Ceased
- 2016-09-30 MX MX2018003861A patent/MX2018003861A/es unknown
- 2016-09-30 HK HK18114640.5A patent/HK1255467A1/zh unknown
- 2016-09-30 CU CUP2018000027A patent/CU20180027A7/xx unknown
- 2016-09-30 CA CA2999937A patent/CA2999937A1/en not_active Abandoned
- 2016-09-30 JP JP2018516488A patent/JP2018533552A/ja active Pending
-
2018
- 2018-03-19 IL IL258231A patent/IL258231A/en unknown
- 2018-03-20 PH PH12018500605A patent/PH12018500605A1/en unknown
- 2018-03-22 SV SV2018005656A patent/SV2018005656A/es unknown
- 2018-03-23 NI NI201800042A patent/NI201800042A/es unknown
- 2018-03-26 EC ECIEPI201823286A patent/ECSP18023286A/es unknown
- 2018-03-26 CL CL2018000786A patent/CL2018000786A1/es unknown
- 2018-03-26 DO DO2018000082A patent/DOP2018000082A/es unknown
- 2018-03-28 CO CONC2018/0003466A patent/CO2018003466A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR3041640A1 (enExample) | 2017-03-31 |
| CN108137582A (zh) | 2018-06-08 |
| CR20180176A (es) | 2018-05-31 |
| AU2016333508A1 (en) | 2018-04-12 |
| MA43021A (fr) | 2018-08-08 |
| WO2017055533A1 (en) | 2017-04-06 |
| EP3356364A1 (en) | 2018-08-08 |
| DOP2018000082A (es) | 2018-10-15 |
| CO2018003466A2 (es) | 2018-07-10 |
| NI201800042A (es) | 2018-06-21 |
| PH12018500605A1 (en) | 2018-09-24 |
| JP2018533552A (ja) | 2018-11-15 |
| ECSP18023286A (es) | 2018-04-30 |
| PE20190337A1 (es) | 2019-03-07 |
| HK1255467A1 (zh) | 2019-08-16 |
| US20180273538A1 (en) | 2018-09-27 |
| MX2018003861A (es) | 2018-08-16 |
| KR20180054856A (ko) | 2018-05-24 |
| TN2018000087A1 (en) | 2019-07-08 |
| BR112018005851A2 (pt) | 2018-10-09 |
| IL258231A (en) | 2018-05-31 |
| FR3041640B1 (fr) | 2019-05-17 |
| EA201890820A1 (ru) | 2018-10-31 |
| SV2018005656A (es) | 2018-08-10 |
| CL2018000786A1 (es) | 2018-09-28 |
| CA2999937A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002155A1 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| NI201800128A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| SV2018005656A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene | |
| CO2018005369A2 (es) | Inhibidores triazol de acc y usos de los mismos | |
| CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
| CO2018000668A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2017002908A1 (es) | Amidas heterocíclicas como inhibidores de quinasa. | |
| CR20150395A (es) | Derivados de pirrolo[2,3-d] pirimidina | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| CR20150436A (es) | Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| NI201500119A (es) | Compuestos de heteroarilo y sus usos | |
| CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| MX374191B (es) | Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| CU20130124A7 (es) | Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia | |
| ECSP17063489A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| PY1735113A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos |